1-20 of 53
Marie-Sarah Dilhuydy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study

Paul J. Hampel, Kari G. Rabe, Romain Guieze, Yucai Wang, Emmanuelle Ferrant, Saad S. Kenderian, Marie Sarah Dilhuydy, Eli Muchtar, Anne-Sophie Michallet, Jose F. Leis, Luca Inchiappa, Mazie Tsang, Aline Clavert, Talal Hilal, Stephane Lepretre, Ricardo D. Parrondo, Emmanuelle Tchernonog, Amber Koehler, Lin Wang, Susan M. Schwager, Susan L. Slager, Neil E. Kay, Luc-Matthieu Fornecker, Sameer A. Parikh, Loic Ysebaert
Journal: Blood
Blood (2024) 144 (Supplement 1): 1856.
https://doi.org/10.1182/blood-2024-198200
Published: 2024
Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Anne Sophie Michallet, Remi Letestu, Magali Legarff, Stéphane Morisset, Therese Aurran-Schleinitz, Kamel Laribi, Vincent Levy, Laurence Simon, Damien Roos Weil, Marie Sarah Dilhuydy, Cecile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie De Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Lepretre, Philippe Carassou, Julie Gay, Benedicte Hivert, Luc-Matthieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Omar Benbrahim, Xavier Cahu, Florence Nguyen Khac, Valerie Rouillé, Loic Ysebaert, Anne Quinquenel
Journal: Blood
Blood (2024) 144 (Supplement 1): 584.
https://doi.org/10.1182/blood-2024-194593
Published: 2024
Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Tavernier Magali, Stéphane Morisset, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos Weil, Veronique Leblond, Marie Sarah Dilhuydy, Cecile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie De Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Lepretre, Philippe Carassou, Julie Gay, Benedicte Hivert, Luc Matthieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valerie Rouillé, Alain Jacques Delmer
Journal: Blood
Blood (2023) 142 (Supplement 1): 3268.
https://doi.org/10.1182/blood-2023-173341
Published: 2023
Journal Articles

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group

Loic Ysebaert, Emmanuelle Ferrant, Marie Sarah Dilhuydy, Anne-Sophie Michallet, Luca Inchiappa, Romain Guieze, Emmanuelle Tchernonog, Ana Cavillon, Marie Christine Bene, Luc-Matthieu Fornecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3273.
https://doi.org/10.1182/blood-2023-180696
Published: 2023
Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Christelle Portois, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan, Jean-Pierre Vilque, Therese Aurran Schleinitz, Cymbalista Florence, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen Khac, Pierre Feugier
Journal: Blood
Blood (2022) 140 (Supplement 1): 7013–7015.
https://doi.org/10.1182/blood-2022-157963
Published: 2022
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Anne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Therese Aurran-Schleinitz, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Véronique Leblond, Marie-Sarah Dilhuydy, Caroline Dartigeas, Cecile Tomowiak, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stephane Lepretre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen Khac, Valérie Rouille, Alain Delmer, Anne-Sophie Michallet
Journal: Blood
Blood (2022) 140 (Supplement 1): 7007–7009.
https://doi.org/10.1182/blood-2022-159678
Published: 2022
Journal Articles

Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group

Charlotte Doublet, Marie-Sarah Dilhuydy, Emmanuelle Ferrant, Pierre Feugier, Alexandra Fayault, Philippine Robert, Stephane Lepretre, Alain Delmer, Cécile Tomowiak, Romain Guieze, Kamel Laribi, Marguerite Vignon, Aline Clavert, Fontanet Bijou, Daniel Re, Diane Lara, Fatiha Merabet, Emmanuelle Tchernonog, Caroline Dartigeas, Anne-Sophie Michallet, Anne Quinquenel
Journal: Blood
Blood (2021) 138 (Supplement 1): 3747.
https://doi.org/10.1182/blood-2021-149640
Published: 2021
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Mad-Helenie Elsensohn, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Veronique Leblond, Marie-Sarah Dilhuydy, Cécile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Leprêtre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen-Khac, Valérie Rouille, Alain Delmer
Journal: Blood
Blood (2021) 138 (Supplement 1): 641.
https://doi.org/10.1182/blood-2021-145624
Published: 2021
Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Clinical Trials & Observations Brief Report
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanei, Michel Ticchioni, Marie-Sarah Dilhuydy, Fabien Subtil, Valerie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Gilles Salles, Olivier Tournilhac, Alain Delmer, Christelle Portois, Brigitte Pegourie, Veronique Leblond, Cecile Tomowiak, Sophie De Guibert, Frederique Orsini Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc-Matthieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Malgorzata Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran, Florence Cymbalista, Stéphane Lepretre, Vincent Levy, Florence Nguyen-Khac, Pierre Feugier
Journal: Blood
Blood (2021) 137 (8): 1019–1023.
https://doi.org/10.1182/blood.2020008164
Published: 2021
Includes: Supplemental data
Journal Articles

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, MD, Bruno Villemagne, MD, Gilles A. Salles, MD PhD, Olivier Tournilhac, Alain Jacques Delmer, MD PhD, Christelle Portois, Brigitte Pegourie, MD, Veronique Leblond, MD PhD, Cecile Tomowiak, MD, Sophie de Guibert, MD, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, MD PhD, Loic Ysebaert, MD PhD, Caroline Dartigeas, MD, Margot Truchan, Jean Pierre Vilque, Thérèse Aurran, MD, Florence Cymbalista, MD PhD, Stephane Lepretre, Vincent Levy, MD PhD, Florence Nguyen-Khac, MD PhD, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3038.
https://doi.org/10.1182/blood-2019-126720
Published: 2019
Journal Articles

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

Brief Report
Anne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, Loïc Ysebaert, Carole Fleury, Grégory Lazarian, Marie-Sarah Dilhuydy, Delphine Nollet, Romain Guieze, Pierre Feugier, Damien Roos-Weil, Lise Willems, Anne-Sophie Michallet, Alain Delmer, Katia Hormigos, Vincent Levy, Florence Cymbalista, Fanny Baran-Marszak
Journal: Blood
Blood (2019) 134 (7): 641–644.
https://doi.org/10.1182/blood.2019000854
Published: 2019
Includes: Supplemental data
Journal Articles

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Anne Quinquenel, Luc Matthieu Fornecker, Remi Letestu, Carole Fleury, Loic Ysebaert, MD PhD, Marie-Sarah Dilhuydy, MD, Romain Guieze, MD, Pierre Feugier, Damien Roos-Weil, MD, Lise Willems, MD, Anne-Sophie Michallet, MD PhD, Alain Jacques Delmer, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Vincent Levy, MD PhD, Florence Cymbalista, MD, Fanny Baran-Marszak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 584.
https://doi.org/10.1182/blood-2018-99-114027
Published: 2018
Journal Articles

Outcome of Patients Receiving Venetoclax for Chronic Lymphocytic Leukemia (CLL) in Real-Life Clinical Practice: Results of the French ATU Program on Behalf of the Filo Group

Florian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, MD, Sandy Amorim, MD, Florence Cymbalista, MD PhD, Charles Herbaux, MD, Sophie de Guibert, MD, Damien Roos-Weil, MD, Benedicte Hivert, MD, Thérèse Aurran, MD, Jehan Dupuis, MD, Anaise Blouet, MD, Emmanuelle Tchernonog, MD, Kamel Laribi, MD, Natalia Dmytruk, MD, Pierre Morel, Anne-Sophie Michallet, MD PhD, Caroline Dartigeas, MD, Laure Farnault, MD, Anne Lavaud, MD, Isabelle Plantier, MD, Jacques-Olivier Bay, MD PhD, Olivier Tournilhac, MD PhD, Alain Jacques Delmer, MD, Pierre Feugier, Loic Ysebaert, MD PhD, Romain Guieze, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5549.
https://doi.org/10.1182/blood-2018-99-118622
Published: 2018
Journal Articles

Kinase Inhibitors (ibrutinib or idelalisib) in the Management of Chronic Lymphocytic Leukemia-Associated Autoimmune Cytopenia: A Retrospective Study of the French Innovative Leukemia Organization (FILO)

Sophie Godet, MD, Anne Quinquenel, Caroline Dartigeas, MD, Loic Ysebaert, MD PhD, Jehan Dupuis, MD, Haykanush Ohanyan, Aude Collignon, Laurent Gilardin, MD MSc, Stéphane Leprêtre, MD, Marie-Sarah Dilhuydy, MD, Marguerite Vignon, MD, Sophie de Guibert, MD, Natalia Dmytruk, MD, Eric Durot, MD, David Ghez, MD PhD, Damien Roos-Weil, MD, Elise Toussaint, MD, Fatiha Merabet, MD, Vincent Levy, MD PhD, Alain Jacques Delmer, MD, Thérèse Aurran, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3152.
https://doi.org/10.1182/blood-2018-99-112654
Published: 2018
Journal Articles

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, MD, Bruno Villemagne, Gilles Andre Salles, MD PhD, Olivier Tournilhac, MD PhD, Alain Jacques Delmer, MD, Christelle Portois, Brigitte Pegourie, MD, Véronique Leblond, MD PhD, Cecile Tomowiak, MD, Sophie de Guibert, MD, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, MD PhD, Caroline Dartigeas, Margot Truchan, Thérèse Aurran, MD, Florence Cymbalista, MD, Stéphane Leprêtre, MD, Vincent Levy, MD PhD, Florence Nguyen-Khac, MD PhD, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier
Journal: Blood
Blood (2018) 132 (Supplement 1): 1858.
https://doi.org/10.1182/blood-2018-99-111977
Published: 2018
Journal Articles

p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial

Magali Le Garff-Tavernier, Claire Quiney, Lauren Veronese, MD PhD, Florence Nguyen-Khac, MD PhD, Pauline Robbe, MSc, PhD, Patricia Combes, Marie-Sarah Dilhuydy, MD, Pierre Feugier, Beatrice Mahe, MD, Laurence Sanhes, MD, Alain Jacques Delmer, MD, Loic Ysebaert, MD PhD, Malgorzata Truchan-Graczyk, Brigitte Dreyfus, MD, Choquet Sylvain, MD, Thérèse Aurran, MD, Emmanuelle Ferrant, MD, Caroline Dartigeas, MD, Stéphane Leprêtre, MD, Gian Matteo Pica, MD, Frederic Davi, MD PhD, Bruno Pereira, Roselyne Delepine, Anna Schuh, MD PhD, Romain Guieze, MD, Jacques-Olivier Bay, MD PhD, Véronique Leblond, MD PhD, Helene Merle-Beral, MD PhD, Sophie de Guibert, MD, Olivier Tournilhac, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3127.
https://doi.org/10.1182/blood-2018-99-116722
Published: 2018
Journal Articles

Dynamic of Telomeric Parameters in Relapsing or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL), an Analysis of the Filo ICLL001 Bomp Trial

Laura Bounaix, Andrei Tchirkov, MD PhD, Florence Nguyen-Khac, MD PhD, Patricia Combes, Pierre Feugier, MD, Laurence Sanhes, Marie-Sarah Dilhuydy, MD, Hussam Saad, MD, Loic Ysebaert, MD PhD, Choquet Sylvain, Jean-Pierre Vilque, Annie Brion, Carla Araujo, MD, Emmanuelle Ferrant, Brigitte Dreyfus, Alain Jacques Delmer, MD, Malgorzata Truchan-Graczyk, Stéphane Leprêtre, MD, Sophie de Guibert, Romain Guieze, MD PhD, Lauren Veronese, MD PhD, Richard Lemal, MD, Philippe Vago, Jacques-Olivier Bay, MD PhD, Marc G. Berger, MD PhD, Anna Schuh, MD PhD, Christophe Ferrand, PhD, Roselyne Delepine, Véronique Leblond, Olivier Tournilhac, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4285.
https://doi.org/10.1182/blood.V130.Suppl_1.4285.4285
Published: 2017
Journal Articles

Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, Bruno Villemagne, Gilles Andre Salles, MD PhD, Olivier Tournilhac, MD PhD, Alain Jacques Delmer, MD, Christelle Portois, Brigitte Pegourie, MD, Veronique Leblond, Cecile Tomowiak, MD, Sophie de Guibert, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, MD PhD, Caroline Dartigeas, Margot Truchan, Thérèse Aurran, MD, Florence Cymbalista, MD, Stéphane Leprêtre, MD, Vincent Levy, MD PhD, Florence Nguyen Khac, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 497.
https://doi.org/10.1182/blood.V130.Suppl_1.497.497
Published: 2017
Journal Articles

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Jennifer R. Brown, MD PhD, Javid Moslehi, MD, Michael S. Ewer, MD MPH, JD, Susan M. O'Brien, MD, Paolo Ghia, MD PhD, Florence Cymbalista, MD, Tait D. Shanafelt, MD, Graeme Fraser, MD, Simon Rule, MD, Steven E. Coutre, MD, Marie-Sarah Dilhuydy, MD, Paula Cramer, MD, Ulrich Jaeger, MD, Martin Dreyling, MD, John C. Byrd, MD, Steven Treon, MD PhD, Emily Liu, Stephen Chang, PhD, Amulya Bista, Rama Vempati, Lisa Boornazian, BSN, Rudolph Valentino, PharmD, Vijay Reddy, MD PhD, Michelle Mahler, MD, Huiying Yang, MD PhD, Jan A. Burger, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1743.
https://doi.org/10.1182/blood.V130.Suppl_1.1743.1743
Published: 2017
Journal Articles

A Retrospective Analysis of 450 TP53 Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Fanny Baran-Marszak, MD PhD, Valerie Vidal, Myriam Hormi, Virginie Eclache, Lauren Veronese, MD PhD, Olivier Tournilhac, MD PhD, Frederic Davi, Florence Nguyen-Khac, MD PhD, Veronique Leblond, Eric Delabesse, MD PhD, Loic Ysebaert, MD PhD, Audrey Bidet, PharmD, Marie-Sarah Dilhuydy, MD, Stephanie Poulain, MD PhD, Charles Herbaux, Marie-Helene Estienne, PharmD, Caroline Dartigeas, Cedric Pastoret, MD, Sophie de Guibert, Stephane Giraudier, MD PhD, Jehan Dupuis, MD, Pascale Cornillet-Lefebvre, Anne Quinquenel, Sophy Laibe, Thérèse Aurran, MD, Dina Naguib, MD MASTERS, Xavier Troussard, MD, Pierre Sujobert, MD PhD, Anne-Sophie Michallet, MD PhD, Catherine Thieblemont, MD PhD, Remi Letestu, Gregory Lazarian, PharmD, Vincent Levy, MD PhD, Thierry Soussi, Sophie Raynaud, MD PhD, Florence Cymbalista, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1722.
https://doi.org/10.1182/blood.V130.Suppl_1.1722.1722
Published: 2017